Global Coronary Artery Disease Therapeutics Market 2017-2021
- SKU ID : TNV-IRTNTR15496 11197982
- |
- Publishing Date: 31-Oct-2017
- |
- Region: Global
- |
- No. of pages: 100
About Coronary Artery Disease Therapeutics
Coronary artery disease (CAD) is the most common type of heart disease and is one of the leading causes of death globally. It can lead to complications including myocardial infarction, stable angina, unstable angina, and sudden cardiac death. CAD is the narrowing of the coronary arteries that prevents the supply of an adequate amount of blood supply to the heart. It happens when a coronary artery gets hardened or narrowed due to various reasons such as the build-up of cholesterol or other materials known as plaque on the inner wall of the artery. This build-up is known as atherosclerosis. With passing time, a lesser amount of blood flows through the arteries. As a result heart muscle fails to get the required amount of blood or oxygen.
Technavio’s analysts forecast the global coronary artery disease therapeutics market to grow at a CAGR of 5.17% during the period 2017-2021.
Covered in this report
The report covers the present scenario and the growth prospects of the global coronary artery disease therapeutics market for 2017-2021. To calculate the market size, the report considers the sales of branded, generic, and off-label drugs.
The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA
Technavio's report, Global Coronary Artery Disease Therapeutics Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors
• AstraZeneca
• Gilead
• Novartis
• Pfizer
Other prominent vendors
• Bayer,
• Bristol-Myers Squibb,
• GlaxoSmithKline,
• Merck,
• Mylan,
• Teva Pharmaceutical Industries
Market driver
• Growing geriatric population
• For a full, detailed list, view our report
Market challenge
• Highly genericized market
• For a full, detailed list, view our report
Market trend
• Growing strategic alliances
• For a full, detailed list, view our report
Key questions answered in this report
• What will the market size be in 2021 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.
Coronary artery disease (CAD) is the most common type of heart disease and is one of the leading causes of death globally. It can lead to complications including myocardial infarction, stable angina, unstable angina, and sudden cardiac death. CAD is the narrowing of the coronary arteries that prevents the supply of an adequate amount of blood supply to the heart. It happens when a coronary artery gets hardened or narrowed due to various reasons such as the build-up of cholesterol or other materials known as plaque on the inner wall of the artery. This build-up is known as atherosclerosis. With passing time, a lesser amount of blood flows through the arteries. As a result heart muscle fails to get the required amount of blood or oxygen.
Technavio’s analysts forecast the global coronary artery disease therapeutics market to grow at a CAGR of 5.17% during the period 2017-2021.
Covered in this report
The report covers the present scenario and the growth prospects of the global coronary artery disease therapeutics market for 2017-2021. To calculate the market size, the report considers the sales of branded, generic, and off-label drugs.
The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA
Technavio's report, Global Coronary Artery Disease Therapeutics Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors
• AstraZeneca
• Gilead
• Novartis
• Pfizer
Other prominent vendors
• Bayer,
• Bristol-Myers Squibb,
• GlaxoSmithKline,
• Merck,
• Mylan,
• Teva Pharmaceutical Industries
Market driver
• Growing geriatric population
• For a full, detailed list, view our report
Market challenge
• Highly genericized market
• For a full, detailed list, view our report
Market trend
• Growing strategic alliances
• For a full, detailed list, view our report
Key questions answered in this report
• What will the market size be in 2021 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.
Frequently Asked Questions
This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.
- By product type
- By End User/Applications
- By Technology
- By Region
The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.
Please Select a Format
